TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options Under Clinical Evaluation for Newly Diagnosed Childhood Nasopharyngeal Carcinoma
Source: Childhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: August 23, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Newly Diagnosed Childhood Nasopharyngeal Carcinoma
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
ARAR2221 (NCT06064097) (A Study Using Nivolumab, in Combination with Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma): This study will evaluate the safety of combining induction chemotherapy with an anti-PD-1 immune checkpoint inhibitor (nivolumab) in children, adolescents, and young adults with nasopharyngeal carcinoma. It will also estimate the 2-year EFS rate of patients treated with induction chemoimmunotherapy using gemcitabine and cisplatin, followed by consolidation chemotherapy, radiation therapy, immunotherapy (cisplatin, nivolumab, and response-adjusted, dose de-escalated radiation therapy), and nivolumab maintenance therapy. The treatment plan in the ARAR2221 trial was modeled after therapy that was effective in phase III trials for adults with nasopharyngeal carcinoma.
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Preserved source evidence · Not medical advice